ElonRMusk
Oct 8, 3:07 PM
$PYXS Overall assessment -
Pyxis has a credible early clinical signal and a substantially improved cash position. Those are real positives. But the financing was highly dilutive, the Phase 3 program is not fully covered by current funds unless warrants are exercised or more capital is raised, and the clinical evidence remains too early to call MICVO a proven asset.
I’d classify PYXS as a high-risk, catalyst-driven biotech investment, not a straightforward low-priced value stock. The
$2.02 quote is less important than the roughly
$240–245 million basic equity value, the potential 69 million additional shares from the two major warrant blocks, and whether the Phase 1 signal survives a randomized Phase 3 test. A bullish investor can make a case for meaningful upside if MICVO works; a cautious investor can reasonably wait for combination data, further survival follow-up, or clearer Phase 3 funding before deciding whether that risk is worth taking.
0 replies
